Discrete-Choice Experiment to Understand the Preferences of Patients with Hormone-Sensitive Prostate Cancer in the USA, Canada, and the UK

Juan Marcos Gonzalez (), Arijit Ganguli, Alicia K. Morgans, Bertrand F. Tombal, Sebastien J. Hotte, Hiroyoshi Suzuki, Hemant Bhadauria, Mok Oh, Charles D. Scales, Matthew J. Wallace, Jui-Chen Yang and Daniel J. George
Additional contact information
Juan Marcos Gonzalez: Duke University School of Medicine
Arijit Ganguli: Astellas Pharma Inc.
Alicia K. Morgans: Dana-Farber Cancer Institute
Bertrand F. Tombal: Cliniques Universitaires Saint-Luc, Université Catholique de Louvain
Sebastien J. Hotte: McMaster University and Juravinski Cancer Centre
Hiroyoshi Suzuki: Toho University Sakura Medical Center
Hemant Bhadauria: Astellas Pharma Inc.
Mok Oh: Astellas Pharma Inc.
Charles D. Scales: Duke University School of Medicine
Matthew J. Wallace: Duke University School of Medicine
Jui-Chen Yang: Duke University School of Medicine
Daniel J. George: Duke University School of Medicine

The Patient: Patient-Centered Outcomes Research, 2023, vol. 16, issue 6, No 4, 607-623

Abstract: Abstract Background Treatment options for patients with metastatic hormone-sensitive prostate cancer (mHSPC) have broadened, and treatment decisions can have a long-lasting impact on patients' quality of life. Data on patient preferences can improve therapeutic decision-making by helping physicians suggest treatments that align with patients' values and needs. Objective This study aims to quantify patient preferences for attributes of chemohormonal therapies among patients with mHSPC in the USA, Canada, and the UK. Methods A discrete-choice experiment survey instrument was developed and administered to patients with high- and very-high-risk localized prostate cancer and mHSPC. Patients chose between baseline androgen-deprivation therapy (ADT) alone and experimentally designed, hypothetical treatment alternatives representing chemohormonal therapies. Choices were analyzed using logit models to derive the relative importance of attributes for each country and to evaluate differences and similarities among patients across countries. Results A total of 550 respondents completed the survey (USA, 200; Canada, 200; UK, 150); the mean age of respondents was 64.3 years. Treatment choices revealed that patients were most concerned with treatment efficacy. However, treatment-related convenience factors, such as route of drug administration and frequency of monitoring visits, were as important as some treatment-related side effects, such as skin rash, nausea, and fatigue. Patient preferences across countries were similar, although patients in Canada appeared to be more affected by concomitant steroid use. Conclusion Patients with mHSPC believe the use of ADT alone is insufficient when more effective treatments are available. Efficacy is the most significant driver of patient choices. Treatment-related convenience factors can be as important as safety concerns for patients.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40271-023-00638-7 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:patien:v:16:y:2023:i:6:d:10.1007_s40271-023-00638-7

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40271

DOI: 10.1007/s40271-023-00638-7

Access Statistics for this article

The Patient: Patient-Centered Outcomes Research is currently edited by Christopher I. Carswell

More articles in The Patient: Patient-Centered Outcomes Research from Springer, International Academy of Health Preference Research
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().